Status
Conditions
Treatments
About
: Interdental papilla deficiency leads to food impaction, problems with phonetics and an unaesthetic appearance. Reconstruction of the deficient papilla is therefore, important. The purpose of study is to compare the VCMX and SCTG in papillae reconstruction. The null hypothesis is that there is no significant difference in clinical outcome for interdental papilla regeneration by volume stable collagen matrix and subepithelial connective tissue graft.
Full description
The loss of interdental papillae can lead to formation of "black triangle/black holes" which may cause cosmetic, phonetics and functional problem(lateral food impaction).It may be due to plaque associated lesions, traumatic oral hygiene procedure, diverging tooth roots following orthodontic treatment, spacing between the teeth, abnormal tooth crown or contour of restoration.Surgical technique includes the pedicle graft procedure,envelop type flap using subepithelial connective tissue grafting(SCTG) or Platelet rich fibrin(PRF) at recipient site. A new volume stable cross linked collagen matrix (VCMX) is one such substitute for soft tissue regeneration.VCMX (fibrogide) is porcine, having only one porous layer which is made up of collagen having crosslinking to provide good volume stability and some elasticity at the same time. Porous layer promote angiogenesis, ingrowth of fibroblast, matrix biosynthesis and tissue integration. Main advantage is ability to maintain good volume stability. Apart from this less pain, less surgical chair time, faster wound healing as compared to connective tissue graft. VCMX shows promising results in term of volume gain, without any adverse reaction in various preclinical and clinical studies of soft tissue augmentation at implant sites.It also shows similar volume gain when augmenting implant sites with SCTG or VCMX. The purpose of study is to compare the VCMX and SCTG in papillae reconstruction. The null hypothesis is that there is no significant difference in clinical outcome for interdental papilla regeneration by volume stable collagen matrix and subepithelial connective tissue graft.
MATERIAL AND METHODS:
The present Prospective, analytical,Randomized Controlled clinical trial will be conducted in the Department of Periodontics and Oral Implantology, Post Graduate Institute of Dental Sciences,Rohtak. In order to guarantee balance in patients allocated to either group ,block randomization will be used .Allocation concealment will be performed by a study monitor, preparing the assignment in opaque, sealed envelopes. Single blinding will be adopted where investigator analysing the result will be unaware to which group the patient belongs. Patient will be educated about the papillary recession and its implications. Scaling and root planing will be performed if needed. Thirty six Patients enrolled in the study will be randomly divided into two groups: TEST GROUP (n= 18) in which volume stable collagen matrix will be placed at the recipient site created by Han & Takei procedure in the deficient interdental papilla and CONTROL GROUP (n=18) in which subepithelial connective tissue graft will be harvested from donor site and placed at the recipient site created by Han & Takei procedure in the deficient interdental papilla. Patients will be re-evaluated for papillary fill after 1 month,3 months, 6 months respectively. Primary outcome measures includes Gain in papillary height in terms of distance measured from tip of papilla to an imaginary line connecting most apical point of gingival zenith of adjacent teeth. secondary outcomes include Full mouth indices Gingival Index (GI),Plaque Index (PI) Site specific Indices Gingival Index(GI), Plaque Index(PI), Papillary bleeding index ,Pocket Probing Depth (PPD), Clinical attachment loss(CAL), Width of keratinized gingiva(WKG), Distance from contact point to tip of papilla(CP-TP), Healing Index(HI)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
36 participants in 2 patient groups
Loading...
Central trial contact
Nishi Tanwar, MDS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal